Corrigendum to “Glucagon-like Peptide 1 Agonist Use in an Adult With Cystic Fibrosis–Related Diabetes and Metabolic Syndrome”
AACE Endocrinology and Diabetes · 2026-03 · 13 (2) · 373
DOI: 10.1016/j.aed.2026.01.002 ↗Kurz gefasst
Korrektur in der Zeitschrift AACE Endocrinology and Diabetes, 2026-03. Verfasst von Roger Auth und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Pulmonary Critical Care and Sleep, Alpert Medical School of Brown University, Providence, Rhode Island. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
[This corrects the article DOI: 10.1016/j.aed.2025.03.011.].
Autor:innen und Institutionen
- Department of Medicine, Division of Pulmonary Critical Care and Sleep, Alpert Medical School of Brown University, Providence, Rhode Island.
- Division of Endocrinology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
- Division of Pediatric Endocrinology, Brown University Health, Providence, Rhode Island.
Zitieren
APA
Auth, R., Dougherty, B., Putman, M., & Scully, K. (2026). Corrigendum to “Glucagon-like Peptide 1 Agonist Use in an Adult With Cystic Fibrosis–Related Diabetes and Metabolic Syndrome”. AACE Endocrinology and Diabetes, 13(2), 373. https://doi.org/10.1016/j.aed.2026.01.002
Vancouver
Auth R, Dougherty B, Putman M, Scully K. Corrigendum to “Glucagon-like Peptide 1 Agonist Use in an Adult With Cystic Fibrosis–Related Diabetes and Metabolic Syndrome”. AACE Endocrinology and Diabetes. 2026;13(2):373. doi:10.1016/j.aed.2026.01.002
BibTeX
@article{Auth2026,
author = {Auth, Roger and Dougherty, Brian and Putman, Melissa and Scully, Kevin},
title = {Corrigendum to “Glucagon-like Peptide 1 Agonist Use in an Adult With Cystic Fibrosis–Related Diabetes and Metabolic Syndrome”},
journal = {AACE Endocrinology and Diabetes},
year = {2026},
volume = {13},
number = {2},
pages = {373},
doi = {10.1016/j.aed.2026.01.002}
}
EUVIMED